{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"7"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"48"}],"units":"Participants"}],"groups":[{"description":"Participants received carfilzomib (CFZ) 1.2 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG000","title":"CFZ 1.2 mg/m²"},{"description":"Participants received carfilzomib 2.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG001","title":"CFZ 2.4 mg/m²"},{"description":"Participants received carfilzomib 4.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG002","title":"CFZ 4.0 mg/m²"},{"description":"Participants received carfilzomib 6.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG003","title":"CFZ 6.0 mg/m²"},{"description":"Participants received carfilzomib 8.4 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG004","title":"CFZ 8.4 mg/m²"},{"description":"Participants received carfilzomib 11.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG005","title":"CFZ 11.0 mg/m²"},{"description":"Participants received carfilzomib 15.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG006","title":"CFZ 15.0 mg/m²"},{"description":"Participants received carfilzomib 20.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG007","title":"CFZ 20.0 mg/m²"},{"description":"Participants received carfilzomib 27.0 mg/m² administered by intravenous bolus on Days 1, 2, 8, 9, 15 and 16 in 28-day treatment cycles for up to 12 cycles.","id":"BG008","title":"CFZ 27.0 mg/m²"},{"description":"Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles.","id":"BG009","title":"CFZ 20/27 mg/m²"},{"description":"Participants received carfilzomib 20 mg/m² administered by intravenous bolus on Cycle 1 Days 1, 2, 8, 9, 15 and 16, then 27 mg/m² in all subsequent cycles, for up to 12 cycles. Participants also received 20 mg dexamethasone (DEX) administered before each dose of carfilzomib (i.e. 40 mg weekly).","id":"BG010","title":"CFZ 20/27 mg/m² + DEX"},{"description":"Total of all reporting groups","id":"BG011","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"17.47","value":"62.5"},{"groupId":"BG001","spread":"4.80","value":"69.6"},{"groupId":"BG002","spread":"21.71","value":"55.3"},{"groupId":"BG003","spread":"6.20","value":"51.7"},{"groupId":"BG004","spread":"9.15","value":"61.6"},{"groupId":"BG005","spread":"3.76","value":"61.3"},{"groupId":"BG006","spread":"12.99","value":"50.3"},{"groupId":"BG007","spread":"11.99","value":"60.6"},{"groupId":"BG008","spread":"9.82","value":"67.6"},{"comment":"Not applicable for Part 2 groups","groupId":"BG009","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 2 groups","groupId":"BG010","spread":"NA","value":"NA"},{"groupId":"BG011","spread":"12.25","value":"60.6"}]}],"title":"Dose Escalation (Part 1)"},{"categories":[{"measurements":[{"comment":"Not applicable for Part 1 groups","groupId":"BG000","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG001","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG002","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG003","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG004","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG005","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG006","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG007","spread":"NA","value":"NA"},{"comment":"Not applicable for Part 1 groups","groupId":"BG008","spread":"NA","value":"NA"},{"groupId":"BG009","spread":"9.21","value":"66.3"},{"groupId":"BG010","spread":"13.57","value":"54.3"},{"groupId":"BG011","spread":"11.96","value":"61.9"}]}],"title":"Dose Expansion (Part 2)"}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"22"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"5"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"26"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"},{"groupId":"BG010","value":"1"},{"groupId":"BG011","value":"3"}]}],"title":"African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"6"},{"groupId":"BG010","value":"3"},{"groupId":"BG011","value":"42"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"2"}]}],"title":"Native American"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"4"},{"groupId":"BG011","value":"28"}]}],"title":"Multiple Myeloma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"17"}]}],"title":"Non-Hodgkin's Lymphoma"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"2"}]}],"title":"Waldenstrom's Macroglobulinemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"0"},{"groupId":"BG011","value":"1"}]}],"title":"Hodgkin's Disease"}],"paramType":"NUMBER","title":"Disease Diagnosis","unitOfMeasure":"participants"}]}